Mode
Text Size
Log in / Sign up

Periodontitis and chronic liver disease linked through proposed oral-gut-liver axisConceptual framework links liver, gut, immune, and oral health

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider the proposed oral-gut-liver axis as a hypothesis, not a proven causal pathway.

This narrative review introduces the concept of a Liver-Gut-Immune-Oral Axis as a framework linking periodontitis and chronic liver disease. The authors synthesize evidence from mechanistic and associative studies to propose bidirectional pathways: periodontitis may exacerbate liver inflammation via oral pathogens entering the gut-liver circulation, while chronic liver disease may alter immune and metabolic states that worsen periodontal health. The review emphasizes that these pathways are currently inferred, not causally proven.

Key strategies discussed include targeting tissue inflammation (TI) with metabolic modulators, epigenetic drugs, or periodontal interventions to disrupt the proposed cycle. The authors suggest this approach could advance precision medicine for inflammatory comorbidities. However, they explicitly caution that the validity of the axis as an integrated, causally-linked biological system awaits direct experimental validation.

No specific study populations, sample sizes, interventions, or outcomes are reported, as this is a conceptual review. The review does not provide pooled effect sizes or quantitative results. Clinicians should interpret the proposed axis as a hypothesis-generating framework rather than a basis for clinical action. The authors acknowledge that causal links between the components remain unconfirmed.

This narrative review explores the Liver-Gut-Immune-Oral Axis, a conceptual framework connecting chronic liver disease and periodontitis. The authors discuss how these conditions might be linked through a cycle of inflammation. However, the review notes that this integrated biological system has not yet been directly validated by experimental studies.

The forward and reverse pathways described are currently inferred from mechanistic and associative studies rather than proven causal links. This means the connection remains a theoretical model based on existing evidence. The review highlights that targeting this axis with metabolic modulators or periodontal interventions could offer strategies for precision medicine.

Readers should understand that while this framework is interesting, it awaits direct experimental validation. The validity of this axis as a causally-linked system is not yet confirmed. Until more direct evidence is available, these connections should be viewed as a hypothesis rather than a proven fact.

What this means for you:
This conceptual framework links liver and oral health, but direct experimental validation is still needed.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Trained immunity (TI) reveals that innate immune cells acquire long-term functional memory through metabolic and epigenetic reprogramming. This review examines TI in chronic liver diseases and periodontitis, proposing the “Liver-Gut-Immune-Oral Axis” as a framework where TI bridges these comorbidities. The forward pathway, currently inferred from mechanistic and associative studies, proposes that liver-gut dysfunction induces bone marrow training, generating hyper-reactive monocytes that amplify periodontal inflammation. The reverse pathway, similarly conceptual, proposes that periodontal pathogens reprogram hematopoietic progenitors, accelerating liver disease progression. Both converge on shared metabolic-epigenetic reprogramming circuits. We emphasize that this axis represents a conceptual framework synthesized from current mechanistic and associative evidence; its validity as an integrated, causally-linked biological system awaits direct experimental validation. Targeting TI with metabolic modulators, epigenetic drugs, or periodontal interventions offers strategies to disrupt this cycle and advance precision medicine for inflammatory comorbidities.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.